All articles from Quotient Bioresearch

Quotient receives final patent approval for its Enterion™ technology – the industry’s leading clinical technology for investigating drug absorption
May 2, 2012

• Quotient Clinical, part of Quotient Bioresearch ("Quotient") announced today that it has received approval of the final patent for its Enterion^TM technology. This completes a portfolio of eight granted patents across North America and Europe, with a lifetime extending through to 2020. The Enterion capsule has been developed to investigate the absorption of drugs from the gastrointestinal (GI) tract.  It is a remote-controlled device that is capable of precisely delivering pharmaceutically relevant drug formulations (both liquids and solids) to specific sites within the GI tract...

Quotient showcases ICHM3 exploratory clinical trials at ASCPT
Mar 8, 2012

• Quotient Clinical, a business unit of Quotient Bioresearch ("Quotient"), will present two significant poster publications at the forthcoming American Society for Clinical Pharmacology and Therapeutics (ASCPT) meeting to be held on March 12th to 17th in Maryland, USA...

Quotient Bioresearch secures investment for next phase of growth
Jan 23, 2012

• Quotient Bioresearch ("Quotient") has today announced a management buyout financed by TA Associates, the existing private equity shareholder. Terms of the buyout were not disclosed. Quotient is a UK-based provider of outsourced development services, employing over 500 people and serving pharmaceutical and life science customers on a global basis. It has built a broad and innovative service portfolio, principally targeted at the early stages of drug development, and based upon its chemistry, metabolism, bioanalytical and clinical capabilities...
  

Quotient’s PK/PD Seminar leads the way
Oct 31, 2011

• Leading academics and delegates from around the world gathered last week for Quotient Bioresearch's Autumn Seminar into the latest approaches in the use of PK, PD and PK/PD modelling in drug development. The seminar, held at Quotient Bioresearch's Bioanalytical Sciences facility in Cambridgeshire, UK saw over 60 delegates from the pharmaceutical industry meet to hear a series of presentations and take part in lively debate with key academics and industry thought-leaders...

Quotient Bioresearch Announces First Use of Bruker Maldi Biotyper for Bacterial Identification
Sep 21, 2011

• Quotient Bioresearch has today announced its adoption of Bruker's MALDI Biotyper for bacterial identification, following a successful year-long trial. The announcement, made at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) where Quotient presented a series of posters, places the company in a unique position as the first GLP laboratory to adopt the technology for routine bacterial identification as part of its portfolio of services for antimicrobial development...

Quotient announces agreement with Phico Therapeutics and first application of RapidFACT for nasal delivery
Sep 16, 2011

• Quotient Clinical, a business unit of Quotient Bioresearch (Quotient), today announced an agreement with UK-based biotech, Phico Therapeutics (Phico). Quotient will undertake a RapidFACTTM program to optimise nasal delivery of Phico's SASPjectTM PT1.2, an antibiotic protein technology that offers a new approach for the treatment of serious life-threatening bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA)...

Quotient announces new RapidFACT program with MediGene
Aug 10, 2011

• Quotient Clinical, a business unit of Quotient Bioresearch (Quotient), today announced an agreement with MediGene AG (MediGene), the German biotechnology company, to undertake a RapidFACTTM formulation development and clinical testing program on RhuDex®, subject to ethical and Medicines and Healthcare products Regulatory Agency (MHRA) approval...

Quotient Bioresearch sparks debate on bioanalysis
Jun 23, 2011

• The challenges and solutions for the bioanalysis industry were top of the agenda for last week's exclusive bioanalysis seminar organised by Quotient Bioresearch in Munich, Germany. The seminar was attended by representatives from pharmaceutical and biotechnology organisations across Europe and featured debates and panel discussions from leading industry speakers on new techniques and hot topics including the latest industry guidelines...

Quotient Clinical expands clinical capacity in response to customer adoption of its Synthesis-to-Clinic human ADME service
Jun 20, 2011

• Quotient Clinical, a business unit of Quotient Bioresearch ("Quotient"), today announced the completion of a major expansion of its clinical facilities in Nottingham, UK. Bed capacity has been increased by 50 per cent and a dedicated sample processing laboratory for human ADME studies has been incorporated. The new facilities have been inspected and approved for use by the UK regulatory authority, the Medicines and Healthcare products Regulatory Agency (MHRA), and have been awarded Supplementary Accreditation...

Quotient Bioresearch and KWS BioTest partner to deliver end-to-end anti-infectives screening
Jun 7, 2011

• Leading drug development service providers, Quotient Bioresearch Ltd. and KWS BioTest Ltd., have today announced a new strategic partnership to provide a novel co-ordinated approach to support the discovery and development of new antimicrobial agents...

Quotient Bioresearch deploys GxPi’s x-docs™ ‘Server’ EDMS to Manage Vital Documents for the Drug Development Process
Mar 14, 2011

• GxPi, specialists in providing compliant IT solutions to the Life Sciences sector, announced today that their x-docsTM ‘Server' electronic document management solution (EDMS) has been successfully installed and implemented by Quotient Bioresearch across 4 sites in the UK.

Quotient Clinical and Bend Research Announce Collaboration
Nov 15, 2010

• Bend Research Inc. a leading independent drug formulation development and manufacturing company, and Quotient Clinical, a business unit of Quotient Bioresearch a leading developer of compounds through clinical trials, announced today a nonexclusive collaboration that can speed the advance of compounds to clinical trials and expand options for drug delivery.

Quotient Bioresearch to Highlight Integrated Early Stage Drug Development Platforms at FIP Pharmaceutical Sciences World Congress 2010
Oct 13, 2010

• Quotient Bioresearch, a leading provider of early and specialist drug development services, will be highlighting its unique Translational PharmaceuticsTM and Synthesis-to-ClinicTM platforms at FIP Pharmaceutical Sciences World Congress 2010 in association with AAPS Annual Meeting & Exposition, New Orleans, 14-18 November, on booth #3019

Quotient Bioresearch Celebrates Official Opening of New State-of-the-Art Radiochemistry Facility
Sep 15, 2010

• Quotient Bioresearch, a leading provider of early stage and specialist drug development services to pharmaceutical, biotechnology and medical device clients worldwide, has officially opened its new, state-of-the-art radiochemistry facility in Cardiff, UK, with a ceremony including a VIP opening by the First Minister of Wales, Carwyn Jones

New State-of-the-Art Radiochemistry Facility Fully Operational
Jun 22, 2010

• Quotient Bioresearch, a leading provider of early stage and specialist drug development services to pharmaceutical, biotechnology and medical device clients worldwide, today announced that its new, state-of-the-art radiochemistry facility in Cardiff, UK is fully operational and that shipments of radiolabelled products have commenced.

Quotient Bioresearch Presents Comprehensive Drug Development Capabilities via New Company Website
Feb 16, 2010

• Quotient Bioresearch ("Quotient"), a leading provider of early stage and specialist drug development services to pharmaceutical, biotechnology and medical device clients worldwide, announces the launch of its new company website,